Recent research indicates the shingles vaccine may offer benefits beyond preventing the painful viral infection, potentially slowing biological aging in older adults. A University of Southern California study, involving over 3,800 individuals, found vaccinated participants showed reduced signs of biological aging and lower inflammation compared to the unvaccinated.

The study analyzed seven markers of aging, including inflammation, immune function, and brain health. A key finding highlighted the vaccine’s association with lower chronic inflammation, a major driver of age-related decline often called “inflammaging.”

Lead author Jung Ki Kim suggested the vaccine, possibly by preventing viral reactivation, helps reduce this background inflammation. This mechanism could support healthier aging, though the exact biological processes require further understanding.

The findings align with growing evidence that adult vaccines, like those for shingles and flu, are linked to lower dementia risk. This suggests vaccines influence biological processes beyond direct infection prevention.

In the U.S., the CDC recommends the Shingrix vaccine for all adults 50 and older, with no upper age limit. It is also advised for younger adults with weakened immune systems, administered in two doses.

Researchers used data from the U.S. Health and Retirement Study, examining the vaccine’s impact on aging markers. The potential to reduce inflammation positions vaccination as a promising strategy for promoting resilience.

Kim concluded that vaccination could be a valuable addition to broader efforts aimed at slowing age-related decline and supporting long-term health.